DDInter970 DDInter1544
Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol] was approved in 1996.[L5894, L5891]
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Ipratropium {u} (Compound) resembles {v} (Compound) Methylphenidate
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Trospium
Ipratropium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Atropine
Ipratropium {u} (Compound) treats {v} (Disease) asthma
Ipratropium {u} (Compound) binds {v} (Gene) SLC22A4
Ipratropium {u} (Compound) upregulates {v} (Gene) UBQLN2
Ipratropium {u} (Compound) downregulates {v} (Gene) RPS4Y1
Ipratropium {u} (Compound) causes {v} (Side Effect) Flu symptoms
Ipratropium {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hyoscyamine
Ipratropium (Compound) resembles Methylphenidate (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Trospium
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Atropine
Ipratropium (Compound) treats asthma (Disease)
Ipratropium (Compound) binds SLC22A4 (Gene)
Ipratropium (Compound) upregulates UBQLN2 (Gene)
Ipratropium (Compound) downregulates RPS4Y1 (Gene)
Ipratropium (Compound) causes Flu symptoms (Side Effect)
Ipratropium (Compound) resembles Hyoscyamine (Compound) and Ipratropium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine